Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to determine the safety and feasibility of giving a single
dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from
melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after
receiving the study drug.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute